Glenmark Pharmaceuticals is planning to raise funds through issue of debt securities whether denominated in Indian Rupee and/or foreign currency (ies) either by way of a public issue or by way of a private placement in accordance with the provisions of the applicable law, subject to necessary approvals, if any. Proceeds from these debt securities issuance will be used mainly to refinance existing debt.
The meeting of the Board of Directors of the company is scheduled to be held on May 29, 2019, to consider the same.
Glenmark Pharmaceuticals is a global pharmaceutical company. The company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW).
